Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
31 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
000923-H
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors
Participants currently recruited/enrolled
18-110 Years
NHLBI
Lymphocytic
000809-I
A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
Participants currently recruited/enrolled
10-60 Years
NIAID
Colitis
000444-H
Vaccine Responses in Patients with B Cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphocytic
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphocytic
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Lymphocytic
000064-I
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease with Inflammatory Complications
Enrolling by Invitation
18-125 Years
NIAID
Colitis
20-H-0016
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Lymphocytic
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphocytic
19-I-0108
Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients with Chronic Granulomatous Disease
Enrolling by Invitation
8-65 Years
NIAID
Colitis
19-I-0022
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)
Participants currently recruited/enrolled
3-125 Years
NIAID
Colitis
19-H-0111
Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphocytic
19-H-0001
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphocytic
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Lymphocytic
18-C-0026
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Participants currently recruited/enrolled
1-21 Years
NCI
Lymphocytic
17-H-0118
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphocytic
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphocytic
15-H-0016
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphocytic
15-C-0093
Phase I Trial of Turalio(R) (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Participants currently recruited/enrolled
3-35 Years
NCI
Lymphocytic
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphocytic
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphocytic
11-C-0136
Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
Completed Study; data analyses ongoing
2-55 Years
NCI
Lymphocytic
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Lymphocytic
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphocytic
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
No longer recruiting/follow-up only
18-75 Years
NCI
Lymphocytic
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Lymphocytic
08-H-0105
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphocytic
06-H-0190
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)
Completed Study; data analyses ongoing
18-85 Years
NHLBI
Lymphocytic
05-H-0242
A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic Anemia
Completed Study; data analyses ongoing
2-110 Years
NHLBI
Lymphocytic
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Lymphocytic
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Participants currently recruited/enrolled
0-125 Years
NCI
Lymphocytic
82-I-0183
A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut
Participants currently recruited/enrolled
0-75 Years
NIAID
Colitis